Purpose. To report a case of acute hydrops in a 10-year-old child with advanced keratoconus. Case Presentation. A ten-year-old boy diagnosed as having right eye (RE) infectious keratitis, not responding to antimicrobial therapy, was referred to our hospital. The diagnosis of infectious keratitis was established one month prior to his presentation following an episode of acute corneal whitening, pain, and drop in visual acuity. Topical fortified antibiotics followed by topical antiviral therapy were used with no improvement. Slit lamp examination showed significant corneal protrusion with edema surrounding a rupture in Descemet's membrane in the RE. The diagnosis of acute corneal hydrops from advanced keratoconus was highly suspected and confirmed with corneal topography. Conclusion. Although a relatively rare disease at the age of 10 years, keratoconus can be rapidly progressive in the pediatric group. Keratoconus should always be considered in the differential diagnosis of progressive vision loss in this age group.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396912 | PMC |
http://dx.doi.org/10.1155/2015/308348 | DOI Listing |
J Control Release
December 2024
Department of Ophthalmology, Changzhou Third Peopls's Hospital, Changzhou Clinical College of Xuzhou Medical University, 300 Lanlin North road, Changzhou, Jiangsu 213000, China. Electronic address:
Neutrophil extracellular traps (NETs) promote neovascularization during the acute phase after ocular chemical injury, while the local inflammatory acidic environment delays post-injury repair. Currently, the mechanism of NETs promoting neovascularization has not been fully elucidated, and there is a lack of therapeutic strategies to effectively improve the local microenvironment for corneal repair. In this study, we validated the NETs-M2-angiogenic pathway after injury.
View Article and Find Full Text PDFOphthalmic Plast Reconstr Surg
January 2025
The Operation Eyesight Universal Institute for Eye Cancer, Ophthalmic Pathology Laboratory, LV Prasad Eye Institute, Hyderabad, India.
A 40-year-old woman presented with a mass in her OS for 2 years. Examination revealed a large conjunctival lesion on the nasal bulbar conjunctiva OS and a small upper tarsal conjunctival lesion in the OD. Biopsy OD revealed inflammatory granulation tissue, and OS revealed pseudoepitheliomatous hyperplasia with granulation tissue.
View Article and Find Full Text PDFIndian J Ophthalmol
January 2025
Department of Cornea and Anterior Segment, MGM Eye Institute, Raipur, Chhattisgarh, India.
Purpose: To report the health-seeking behaviors of individuals with acute viral conjunctivitis during an outbreak.
Methods: A cross-sectional survey was carried out in the Raipur district of Chhattisgarh after an outbreak of acute conjunctivitis in July-August 2023.
Results: The treatment choices were pharmacies (51.
World J Virol
December 2024
Department of Ophthalmology, University Hospital of Udine, Udine 33100, Italy.
Background: Blepharoconjunctivitis poses a diagnostic challenge due to its diverse etiology, including viral infections. Blepharoconjunctivits can be acute or chronic, self-limiting, or needing medical therapy.
Aim: To review possible viral agents crucial for accurate differential diagnosis in cases of blepharoconjunctivitis.
Ophthalmol Sci
October 2024
Medical Information Center, Kyushu University Hospital, Fukuoka, Japan.
Purpose: Neurotrophic keratopathy is part of the leprosy sequelae and causes progressive deterioration of visual acuity. Although leprosy is bacteriologically curable, there is currently no efficient treatment. Eye drops containing tetrapeptides, phenylalanine-glycine-leucine-methionine-amide (FGLM-NH) and serine-serine-serine-arginine (SSSR), derived from substance P and insulin-like growth factor 1, are clinically efficacious in the treatment of corneal epithelial disorders caused by neurotrophic keratopathy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!